Andera Partners
Investor profile
Venture capital
Deals
26
distinct rounds
Companies
20
backed
Active span
2018–2026
9 yrs
Total round €
€1.8B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- EQT Life Sciences4
- FundPlus4
- Seventure Partners4
- Earlybird Venture Capital3
- GIMV3
- Novo Holdings3
- Pfizer Ventures3
- Sofinnova Partners3
- Bayern Kapital2
- British Patient Capital2
- Canaan Partners2
- Curie Capital2
- First Venture2
- Gilde Healthcare2
- Hadean Ventures2
- High-Tech Gründerfonds (HTGF)2
- INKEF Capital2
- Invus2
- Ireland Strategic Investment Fund2
- LBBW Venture Capital GmbH2
- Lightstone Ventures2
- Medtronic2
- OCCIDENT2
- Omega Funds2
- Oxford Science Enterprises2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Tubulis Technologies | Germany | 2 | €368M |
| HR Path | France | 3 | €325M |
| Fire1 | Ireland | 2 | €139M |
| Amolyt Pharma | France | 1 | €129M |
| Mylight150 | France | 1 | €100M |
| Artios | UK | 1 | €99M |
| Imcheck Therapeutics | France | 1 | €96M |
| T-knife | Germany | 1 | €94M |
| Grey Wolf Therapeutics | UK | 2 | €88M |
| Exciva | Germany | 2 | €60M |
| SoniVie | Italy | 1 | €55M |
| Qovoltis | France | 1 | €45M |
| Bioptimus | France | 1 | €40M |
| TargED Biopharmaceutical | Netherlands | 1 | €39M |
| TargED Biopharmaceuticals | Netherlands | 1 | €39M |
| HighLife | France | 1 | €32M |
| Ingenostrum | Spain | 1 | €25M |
| Medical microinstruments | Italy | 1 | €20M |
| Skysun | Belgium | 1 | €17M |
| Klubb | France | 1 | €0 |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Tubulis Technologies | Series C | €308M | 2025-10 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Fire1 | Other | €116M | 2025-01 |
| HR Path | Other | €113M | 2022-05 |
| HR Path | Debt | €113M | 2022-05 |
| HR Path | Other | €100M | 2019-03 |
| Mylight150 | Other | €100M | 2023-11 |
| Artios | Series D+ | €99M | 2025-11 |
| Imcheck Therapeutics | Other | €96M | 2022-06 |
| T-knife | Series B | €94M | 2021-08 |